Rheumatology (Oxford, England) · 2026
Cycling versus swapping strategies for treatment of psoriatic arthritis after primary tumour necrosis factor inhibitors failure: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tomo Assaina T J, Ratan Piyush, Gonçalves Lívian de Sousa, Marques Tatiana Carvalho, Souza Maria Eduarda Cavalcanti, Finn Laura Carbonera, Rima Juliana de Abreu Abdalla, Moreira Gabriela Stutz Francisco
Аннотация
OBJECTIVES: Biologic DMARDs (bDMARDs) are widely used to treat moderate to severe PsA. TNF inhibitors (TNFi) are the most common initial biologic owing to their long market availability, clinician familiarity and lower cost. However, the optimal strategy following TNFi failure, cycling to another TNFi or swapping to a bDMARD with a different mechanism, remains uncertain. This meta-analysis compared the two strategies in these patients.
METHODS: PubMed, Embase and Cochrane Central were searched for randomized controlled trials and observational studies comparing cycling with swapping in PsA. Outcomes included: (i) lack of response; (ii) 12-month retention; (iii) 24-month retention; and (iv) adverse events. Pooled risk ratios (RR) with 95% CI were calculated.
RESULTS: Five observational studies, including 2300 PsA patients, were analysed; 1517 (66.0%) received cycling and 783 (34.0%) received swapping strategies. Disease duration before the second bDMARD ranged from 3.7 to 12 years. The main cause of discontinuation of the first TNFi before switching was lack of response (including primary non-response and secondary loss of response) according to individual study definitions. No significant differences were observed between groups for lack of response (RR 0.99; 95% CI 0.70-1.41; I2 = 92%), 12-month retention (RR 0.91; 95% CI 0.75-1.10; I2 = 79%), 24-month retention (RR 0.96; 95% CI 0.53-1.75; I2 = 94%) or adverse events (RR 0.94; 95% CI 0.38-2.34; I2 = 71%).
CONCLUSION: Following TNFi failure, cycling and swapping strategies show comparable retention and safety, suggesting that treatment choice may be guided by clinical characteristics and patient preference rather than clear differences in overall effectiveness.
METHODS: PubMed, Embase and Cochrane Central were searched for randomized controlled trials and observational studies comparing cycling with swapping in PsA. Outcomes included: (i) lack of response; (ii) 12-month retention; (iii) 24-month retention; and (iv) adverse events. Pooled risk ratios (RR) with 95% CI were calculated.
RESULTS: Five observational studies, including 2300 PsA patients, were analysed; 1517 (66.0%) received cycling and 783 (34.0%) received swapping strategies. Disease duration before the second bDMARD ranged from 3.7 to 12 years. The main cause of discontinuation of the first TNFi before switching was lack of response (including primary non-response and secondary loss of response) according to individual study definitions. No significant differences were observed between groups for lack of response (RR 0.99; 95% CI 0.70-1.41; I2 = 92%), 12-month retention (RR 0.91; 95% CI 0.75-1.10; I2 = 79%), 24-month retention (RR 0.96; 95% CI 0.53-1.75; I2 = 94%) or adverse events (RR 0.94; 95% CI 0.38-2.34; I2 = 71%).
CONCLUSION: Following TNFi failure, cycling and swapping strategies show comparable retention and safety, suggesting that treatment choice may be guided by clinical characteristics and patient preference rather than clear differences in overall effectiveness.